Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram posiive bacteria
    1.
    发明授权
    Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram posiive bacteria 失效
    口服和保护性单克隆抗体和嵌合抗体,特异于脂蛋白酸的细菌

    公开(公告)号:US08372958B2

    公开(公告)日:2013-02-12

    申请号:US10601171

    申请日:2003-06-23

    IPC分类号: C07K16/00 C12P21/08

    摘要: The present invention encompasses monoclonal and chimeric antibodies that bind to lipoteichoic acid of Gram positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro and enhance protection from lethal infection in vivo. The mouse monoclonal antibody has been humanized and the resulting chimeric antibody provides a previously unknown means to diagnose, prevent and/or treat infections caused by gram positive bacteria bearing lipoteichoic acid. This invention also encompasses a peptide mimic of the lipoteichoic acid epitope binding site defined by the monoclonal antibody. This epitope or epitope peptide mimic identifies other antibodies that may bind to the lipoteichoic acid epitope. Moreover, the epitope or epitope peptide mimic provides a valuable substrate for the generation of vaccines or other therapeutics.

    摘要翻译: 本发明包括与革兰氏阳性细菌的脂磷壁酸结合的单克隆抗体和嵌合抗体。 抗体还结合全细菌,增强体外吞噬细菌和杀死细菌,增强体内致死感染的保护作用。 小鼠单克隆抗体已经人源化,所得到的嵌合抗体提供了以前未知的用于诊断,预防和/或治疗由具有脂磷壁酸的革兰氏阳性细菌引起的感染的方法。 本发明还包括由单克隆抗体限定的脂磷壁酸结合位点的肽模拟物。 该表位或表位肽模拟物鉴定可结合脂磷壁酸表位的其它抗体。 此外,表位或表位肽模拟物为生成疫苗或其他治疗剂提供了有价值的底物。

    Humanized and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
    7.
    发明申请
    Humanized and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria 失效
    对革兰氏阳性菌的脂磷壁酸具有特异性的人源化和嵌合抗体

    公开(公告)号:US20100221822A1

    公开(公告)日:2010-09-02

    申请号:US12317718

    申请日:2008-12-23

    IPC分类号: C12N5/10 C07H21/04 C12N15/62

    摘要: The present invention encompasses monoclonal and chimeric antibodies that bind to lipoteichoic acid of Gram positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro and enhance protection from lethal infection in vivo. The mouse monoclonal antibody has been humanized and the resulting chimeric antibody provides a previously unknown means to diagnose, prevent and/or treat infections caused by gram positive bacteria bearing lipoteichoic acid. This invention also encompasses a peptide mimic of the lipoteichoic acid epitope binding site defined by the monoclonal antibody. This epitope or epitope peptide mimic identifies other antibodies that may bind to the lipoteichoic acid epitope. Moreover, the epitope or epitope peptide mimic provides a valuable substrate for the generation of vaccines or other therapeutics.

    摘要翻译: 本发明包括与革兰氏阳性细菌的脂磷壁酸结合的单克隆抗体和嵌合抗体。 抗体还结合全细菌,增强体外吞噬细菌和杀死细菌,增强体内致死感染的保护作用。 小鼠单克隆抗体已经人源化,所得到的嵌合抗体提供了以前未知的用于诊断,预防和/或治疗由具有脂磷壁酸的革兰氏阳性细菌引起的感染的方法。 本发明还包括由单克隆抗体限定的脂磷壁酸结合位点的肽模拟物。 该表位或表位肽模拟物鉴定可结合脂磷壁酸表位的其它抗体。 此外,表位或表位肽模拟物为生成疫苗或其他治疗剂提供了有价值的底物。

    Monoclonal antibody which agglutinates E. coli having the CS4-CFA/I family protein
    9.
    发明授权
    Monoclonal antibody which agglutinates E. coli having the CS4-CFA/I family protein 有权
    凝集具有CS4-CFA / I家族蛋白的大肠杆菌的单克隆抗体

    公开(公告)号:US07566540B2

    公开(公告)日:2009-07-28

    申请号:US10864803

    申请日:2004-06-10

    IPC分类号: G01N33/53 G01N33/569

    摘要: A monoclonal antibody to a consensus peptide of the formula: VEKNITVTASVDPTIDLLQADGSALPSAVALTYSPA.(SEQ ID NO:1) The monoclonal antibody of the invention binds exclusively to the sequence SAVALTYS (SEQ ID NO:2) and has use as a diagnostic and for prophylaxis against illness arising from E. coli which produce the CS4-CFA/I family of proteins and for treatment of disease arising therefrom.

    摘要翻译: 对于下列公式的共有肽的单克隆抗体:

    VEKNITVTASVDPTIDLLQADGSALPSAVALTYSPA。 (SEQ ID NO:1) 本发明的单克隆抗体专门与SAVALTYS(SEQ ID NO:2)序列结合,并且可用作诊断和预防来自E. 大肠杆菌,其产生CS4-CFA / I家族蛋白质并用于治疗由此产生的疾病。

      Humanized and chimeric antibodies specific for lipoteichoic acid of GRAM positive bacteria
      10.
      发明授权
      Humanized and chimeric antibodies specific for lipoteichoic acid of GRAM positive bacteria 失效
      对GRAM阳性细菌的脂磷壁酸特异的人源化和嵌合抗体

      公开(公告)号:US07511122B2

      公开(公告)日:2009-03-31

      申请号:US11193440

      申请日:2005-08-01

      摘要: The present invention encompasses monoclonal and chimeric antibodies that bind to lipoteichoic acid of Gram positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro and enhance protection from lethal infection in vivo. The mouse monoclonal antibody has been humanized and the resulting chimeric antibody provides a previously unknown means to diagnose, prevent and/or treat infections caused by gram positive bacteria bearing lipoteichoic acid. This invention also encompasses a peptide mimic of the lipoteichoic acid epitope binding site defined by the monoclonal antibody. This epitope or epitope peptide mimic identifies other antibodies that may bind to the lipoteichoic acid epitope. Moreover, the epitope or epitope peptide mimic provides a valuable substrate for the generation of vaccines or other therapeutics.

      摘要翻译: 本发明包括与革兰氏阳性细菌的脂磷壁酸结合的单克隆抗体和嵌合抗体。 抗体还结合全细菌,增强体外吞噬细菌和杀死细菌,增强体内致死感染的保护作用。 小鼠单克隆抗体已经人源化,所得到的嵌合抗体提供了以前未知的用于诊断,预防和/或治疗由具有脂磷壁酸的革兰氏阳性细菌引起的感染的方法。 本发明还包括由单克隆抗体限定的脂磷壁酸结合位点的肽模拟物。 该表位或表位肽模拟物鉴定可结合脂磷壁酸表位的其它抗体。 此外,表位或表位肽模拟物为生成疫苗或其他治疗剂提供了有价值的底物。